These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 24752068)
1. Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model. Borriello L; Montès M; Lepelletier Y; Leforban B; Liu WQ; Demange L; Delhomme B; Pavoni S; Jarray R; Boucher JL; Dufour S; Hermine O; Garbay C; Hadj-Slimane R; Raynaud F Cancer Lett; 2014 Jul; 349(2):120-7. PubMed ID: 24752068 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship of non-peptidic antagonists of neuropilin-1 receptor. Liu WQ; Megale V; Borriello L; Leforban B; Montès M; Goldwaser E; Gresh N; Piquemal JP; Hadj-Slimane R; Hermine O; Garbay C; Raynaud F; Lepelletier Y; Demange L Bioorg Med Chem Lett; 2014 Sep; 24(17):4254-9. PubMed ID: 25091928 [TBL] [Abstract][Full Text] [Related]
3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272 [TBL] [Abstract][Full Text] [Related]
5. Discovery of structure-based small molecular inhibitor of αB-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo. Chen Z; Ruan Q; Han S; Xi L; Jiang W; Jiang H; Ostrov DA; Cai J Breast Cancer Res Treat; 2014 May; 145(1):45-59. PubMed ID: 24710637 [TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673 [TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. Huang SW; Lien JC; Kuo SC; Huang TF Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer. Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403 [TBL] [Abstract][Full Text] [Related]
9. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo. Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437 [TBL] [Abstract][Full Text] [Related]
10. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects. Gao W; Jin K; Lan H; Han N; Cao F; Teng L Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543 [TBL] [Abstract][Full Text] [Related]
11. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Benatar T; Yang W; Amemiya Y; Evdokimova V; Kahn H; Holloway C; Seth A Breast Cancer Res Treat; 2012 Jun; 133(2):563-73. PubMed ID: 21997538 [TBL] [Abstract][Full Text] [Related]
12. RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models. Yadav B; Taurin S; Larsen L; Rosengren RJ Int J Oncol; 2012 Nov; 41(5):1723-32. PubMed ID: 22971638 [TBL] [Abstract][Full Text] [Related]
13. Targeting VEGF-neuropilin interactions: a promising antitumor strategy. Peng K; Bai Y; Zhu Q; Hu B; Xu Y Drug Discov Today; 2019 Feb; 24(2):656-664. PubMed ID: 30315890 [TBL] [Abstract][Full Text] [Related]